Dr. Clay Siegall is a Future Legend in Targeted Therapies
Dr. Clay Siegall is leading the new wave of targeted cancer therapies. Perhaps a few years from now we will be looking at the Seattle Genetics founder and CEO as a legend in cancer treatment. He officially co-founded the Seattle based biotech company in 1998. Since then it has become a leader in providing advanced anti-body conjugates for cancer treatment. The company’s immediate goal is to vastly improve the mortality rate of cancers that have seen no substantial improvements in decades.
Seattle Genetics is responsible for developing the first FDA-approved antibody drug conjugate. Even more impressive it has partnered with multiple drug manufacturers to roll out its impressive string of drugs. Its partners includes prominent manufacturers such as Bayer and Genentech.
When Dr. Clay first founded Seattle Genetics many professionals thought it wouldn’t make it past the startup phase. Although Dr. Clay and Seattle Genetics exceeded those expectations those who doubted all those years ago had reason. At the time it was just a tiny startup with a small team of researchers. Despite its humble beginnings Dr. Clay always had big plans for the company’s future. Seattle Genetics is continually expanding its list of drugs while simultaneously adding more to the development pipeline.
Dr. Clay founded came up with the idea to start Seattle Genetics after a family member was diagnosed with cancer and he was unsatisfied with the chemotherapy treatment. Because of this it is his belief that systematic chemotherapy is soon to be outdated and targeted therapies are the future.
Before founding Seattle Genetics Dr. Clay Siegall he worked as a researcher at various medical organizations. he worked at the National Cancer Institute for 3 years before departing and joining Bristol-Myers Squibb Pharmaceutical Research Institute.
He graduated from the University of Maryland with a B.S. in zoology and George Washington University where he studied genetics.
Dr. Clay has also been recognized for his excellent work several times, being awarded the Pacific Northwest Ernst & Young Entrepreneur of the Year in 2012.